Securities code: Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) securities abbreviation: Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) Announcement No.: 2022014 Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403)
Announcement on subsidiary’s application for bank credit and guarantee for subsidiary in 2022
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records
Contains, misleading statements or material omissions.
1、 Overview of basic information
Guangdong Shuanglin biopharmaceutical Co., Ltd. (hereinafter referred to as “Guangdong Shuanglin”) and Harbin paisficho biopharmaceutical Co., Ltd. (hereinafter referred to as “paisficho”) are wholly-owned subsidiaries of the company. According to the business development needs of Guangdong Shuanglin and paisficho, in order to ensure their normal capital turnover, Guangdong Shuanglin plans to apply for a comprehensive financing credit line of up to 1.2 billion yuan from financial institutions in 2022, and pasfico plans to apply for a comprehensive financing credit line of up to 500 million yuan from financial institutions in 2022. The company intends to provide joint and several liability guarantee for its wholly-owned subsidiaries Guangdong Shuanglin and paisficho within the above limit. The amount and period of each guarantee shall be agreed in the specific contract. The guaranteed units Guangdong Shuanglin and paisficho provided counter guarantee with all assets. The validity period of applying for bank credit and providing guarantee line for subsidiaries is from the date of adoption of the resolution of the general meeting of shareholders deliberating this proposal to the date of adoption of the resolution of the general meeting of shareholders deliberating the application for bank credit and providing guarantee line for subsidiaries in the next year.
Guangdong Shuanglin and paisficho applied to financial institutions for comprehensive financing credit line, and authorized the legal representatives of Guangdong Shuanglin and paisficho to sign relevant documents in the actual process. For the guarantee provided by the company as a wholly-owned subsidiary within the above limit, the legal representative of the company is authorized to sign relevant documents in the actual handling process. For the guarantee required by the subsidiary company beyond the above limit, it shall be separately submitted to the board of directors or the general meeting of shareholders for deliberation according to the situation.
The guarantee does not constitute affiliated guarantee, and the amount of guarantee to be applied for accounts for 175.82% of the company’s audited net assets attributable to shareholders of Listed Companies in 2020. This proposal has been deliberated and adopted at the 10th meeting of the ninth board of directors of the company and needs to be submitted to the general meeting of shareholders for approval before implementation.
2、 Basic information of the guaranteed
1. Basic information of the guaranteed
Company name legal representative registered capital main business domicile shareholding ratio of the company
Professional institutions, recycling of raw plasma, blood purchase,
Recycling of waste materials, research and development of blood products
Production and sales; Biological products, health care and rehabilitation products and food
Research and development of products; Operating the self-produced products and technology of the enterprise, east of Zhanjiang City
The export, transfer and service of Guangdong Shuanglin huanglingmou 39.6 million yuan technology and the import business of 100% equipment, spare parts, raw and auxiliary materials and technology required by the enterprise, No. 1, East Road
However, the state restricts the company to operate or prohibits the import and export of goods and
Except technology; Real estate development; Information consulting services (not required)
Including licensing information consulting services); Road freight transportation (not applicable)
Including dangerous goods).
Blood products (human albumin, intravenous human immunoglobulin)
(pH4), lyophilized intravenous injection of human immunoglobulin (pH4), human Harbin benefit
Immunoglobulin, human fibrinogen, hepatitis B human immune economy and technology direct and inter paisficho Fu Shaolan 54528571 million yuan epidemic globulin, tetanus human immunoglobulin, rabies patient surgery Development Zone joint support immunoglobulin Intravenous injection of 77 shares of hepatitis B human immunoglobulin Siping Road, 100% (pH 4), human coagulation factor VIII, human prothrombin complex, No
Production and sales of giant cell human immunoglobulin). biology
Development of new drugs and biological vaccines based on engineering technology.
2. Financial data of the guaranteed (unit: 10000 yuan)
December 31, 2020 January December 2020
Company name: negative assets
Total assets total liabilities net assets debt ratio total operating income profit net profit
Guangdong Shuanglin 22707567903 15917230% 10497421186 18341
December 31, 2020 (Unaudited) January December 2020 (Unaudited)
Company name: negative assets
Total assets total liabilities net assets debt ratio total operating income profit net profit
Pasfico 888564538696755015970 43.55% 4820903937764756203
3、 Main contents of the guarantee agreement
The main contents of the guarantee agreement shall be jointly negotiated and determined by the company, the guaranteed subsidiary and the bank.
The company will strictly examine and approve guarantee contracts to control risks.
4、 Opinions of the board of directors
The board of directors of the company believes that the company has absolute control over the subsidiary company providing guarantee this time, and the risk of providing guarantee for it is within the controllable range of the company. The subsidiary’s application for financing from the bank is based on its business development needs. The above guarantee is conducive to ensuring the normal capital turnover of the subsidiary and ensuring daily production and operation.
The independent directors of the company believe that Guangdong Shuanglin and paisficho are wholly-owned subsidiaries of the company, with good operation and normal and stable cash flow. The guarantee matters have required the guaranteed unit to provide counter guarantee with all assets, which can effectively control the guarantee risk. The company’s guarantee for its subsidiaries has fulfilled the corresponding decision-making and approval procedures, and there is no behavior damaging the interests of the company and minority shareholders. We unanimously agreed to submit the proposal to the general meeting of shareholders for deliberation.
5、 Accumulated external guarantees and overdue guarantees
As of December 31, 2021, the company’s external guarantee balance was 40 million yuan, accounting for 4.14% of the company’s audited net assets attributable to shareholders of Listed Companies in 2020. The company did not provide loan guarantee for the controlling shareholder and its related parties. In accordance with the relevant provisions of the stock listing rules and the articles of association, the company has fulfilled the obligation of information disclosure of external guarantees and truthfully disclosed the external guarantees of the company.
6、 Documents for future reference
1. Resolutions of the 10th meeting (interim meeting) of the 9th board of directors;
2. Counter guarantee.
It is hereby announced.
Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403)
Board of directors
March 4, 2002
